CDTX Cidara Therapeutics, Inc.

11.70
+0.25  (2.18%)
Previous Close 11.45
Open 11.45
Price To book 2.16
Market Cap 195.07M
Shares 16,673,000
Volume 32,894
Short Ratio 5.16
Av. Daily Volume 50,221

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated June 2016. Data due 4Q 2017.
CD101 IV - STRIVE
Candidemia
Phase 2 data released February 21, 2017 - efficacy not evident, Development to be discontinued.
CD101 Topical - RADIANT
Vulvovaginal candidiasis (VVC)

Latest News

  1. CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibi
  2. Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC
  3. 7:30 am Cidara Therapeutics reports that the Phase 2 RADIANT clinical trial in acute vulvovaginal candidiasi did not show sufficient efficacy to justify further development --shares halted--
  4. Antimicrobials Working Group Announces New Leadership Team
  5. CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  6. Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis
  7. Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis
  8. Coverage initiated on Cidara Therapeutics by H.C. Wainwright
  9. Newly Published Data Reinforce Growing Body of Evidence Supporting Cidara Therapeutics’ Lead Antifungal CD101
  10. Hedge Funds Aren’t Crazy About Cidara Therapeutics Inc (CDTX) Anymore
  11. Cidara Therapeutics, Inc. :CDTX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016
  12. Cidara Therapeutics’ Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies
  13. Is Cidara Therapeutics (CDTX) Stock a Solid Choice Right Now?
  14. CIDARA THERAPEUTICS, INC. Financials
  15. Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results
  16. CIDARA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  17. Cidara Therapeutics to Present Data on Novel Antifungal CD101 at the Global Joint Conference of ICHS and INFOCUS
  18. Cidara Therapeutics and Square 1 Bank Announce $20 Million Credit Facility
  19. Cidara Therapeutics Announces Data from Studies of Novel Antifungal CD101 to be Presented at ACCP and IDWeek Annual Meetings
  20. Cidara Therapeutics Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriter’s Option to Purchase Additional Shares
  21. CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta
  22. Cidara Therapeutics Announces Pricing of Public Offering of Common Stock
  23. Cidara Therapeutics Announces Commencement of Public Offering of Common Stock
  24. CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  25. CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off
  26. CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  27. Cidara Therapeutics Selects First Development Candidate from its CloudbreakTM Immunotherapy Discovery Platform
  28. Cidara Therapeutics Selects First Development Candidate from its CloudbreakTM Immunotherapy Discovery Platform
  29. Cidara Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
  30. CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  31. Cidara Therapeutics Announces Clinical Management Team Changes
  32. Cidara Reports Second Quarter 2016 Financial Results and Provides Corporate Update
  33. Cidara Therapeutics Announces Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting
  34. Cidara Therapeutics to Present at the Cantor Fitzgerald Annual Healthcare Conference
  35. Cidara Therapeutics Expands Management Team
  36. Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis
  37. Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016
  38. Cidara Therapeutics to Present at the Jefferies 2016 Healthcare Conference
  39. FDA Grants QIDP and Fast Track Designation to CD101 Topical, Cidara Therapeutics’ Novel Antifungal Product Candidate
  40. Cidara Reports First Quarter 2016 Financial Results and Provides Corporate Update
  41. Cidara Therapeutics Announces Presentation of Data from its Antifungal Drug Development Programs at ECCMID 2016
  42. Cidara Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference